Chen, Sheng <br/><br/>
A New VMAT-2 Inhibitor NBI-641449 in the Treatment of Huntington Disease.  [electronic resource] 

 -  CNS neuroscience & therapeutics  Aug 2015 
 - 662-71 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1755-5949 
<br/><br/><label>Standard No.: </label>10.1111/cns.12425  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>3,4-Dihydroxyphenylacetic Acid--metabolism<br/>Animals<br/>Cell Survival--drug effects<br/>Corpus Striatum--drug effects<br/>DNA-Binding Proteins<br/>Disease Models, Animal<br/>Dopamine--metabolism<br/>Dopamine and cAMP-Regulated Phosphoprotein 32--metabolism<br/>Dose-Response Relationship, Drug<br/>Female<br/>Homovanillic Acid--metabolism<br/>Huntington Disease--drug therapy<br/>Mice, Transgenic<br/>Motor Activity--drug effects<br/>Nerve Tissue Proteins--metabolism<br/>Neurons--drug effects<br/>Neuroprotective Agents--pharmacology<br/>Nuclear Proteins--metabolism<br/>Serotonin Plasma Membrane Transport Proteins--metabolism<br/>Tyrosine 3-Monooxygenase--metabolism<br/>Vesicular Monoamine Transport Proteins--antagonists & inhibitors